Cystine-Binding Medication Is Poorly Accessible for the Treatment of Cystinuria
Kidney and Blood Pressure Research · 30.06.2026 · 51 (1) · 729-736
DOI: 10.1159/000553298 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney and Blood Pressure Research, online erschienen am 30.06.2026. Verfasst von Xuemi Peng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC Location University of Amsterdam, Nephrology, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Cystinuria, Tiopronin, Cystine. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Cystinuria is a rare inherited disorder characterized by recurrent cystine stone formation. When lifestyle modification and urine alkalinization fail, cystine-binding medication such as tiopronin and D-penicillamine are indicated. Despite proven benefit, their accessibility across Europe appears limited. We hypothesized that access to this medication is restricted and varies substantially between European countries.
Methods
We surveyed physicians affiliated with the European Reference Network for Rare Kidney Diseases (ERKNet) regarding access barriers and prescribing practices. The online questionnaire was completed by 40 clinicians from 15 countries.
Results
Eighty-five percent of respondents had prescribed cystine-binding medication in the past 2 years, with tiopronin being the preferred agent. However, 30% reported having no access to tiopronin at all, and 83% of recent prescribers experienced accessibility problems, including high costs and unfilled prescriptions. Substantial differences were observed both between and within countries. Prescription rates correlated with physicians’ cystinuria caseload.
Discussion
Cystine-binding medication is poorly and inconsistently accessible across Europe. Coordinated efforts are urgently needed to stabilize supply and ensure equitable, affordable access.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amsterdam UMC Location University of Amsterdam, Nephrology, Amsterdam, The Netherlands.
- Amsterdam Cardiovascular Sciences, Diabetes and Hypertensive Diseases, Amsterdam, The Netherlands.
- Department of Endocrinology and Metabolism, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
- RARE-NL foundation, Amsterdam UMC, Amsterdam, The Netherlands.
- Department of Translational Medical Science, University of Campania "L. Vanvitelli", Napoli, Italy.
- Department of Nephrology, Necker-Enfants Malades University Hospital, APHP, Université Paris Cité, Paris, France.
Zitieren
APA
Peng, X., Penninx, B., Marsman, R. F., Capolongo, G., Courbebaisse, M., Knebelmann, B., Trepiccione, F., Emma, F., Servais, A., Hollak, C. E. M., Levtchenko, E. N., & Olde Engberink, R. H. G. (2026). Cystine-Binding Medication Is Poorly Accessible for the Treatment of Cystinuria. Kidney and Blood Pressure Research, 51(1), 729-736. https://doi.org/10.1159/000553298
Vancouver
Peng X, Penninx B, Marsman RF, Capolongo G, Courbebaisse M, Knebelmann B, et al. Cystine-Binding Medication Is Poorly Accessible for the Treatment of Cystinuria. Kidney and Blood Pressure Research. 2026;51(1):729-736. doi:10.1159/000553298
BibTeX
@article{Peng2026,
author = {Peng, Xuemi and Penninx, Bart and Marsman, Roos F and Capolongo, Giovanna and Courbebaisse, Marie and Knebelmann, Bertrand and Trepiccione, Francesco and Emma, Francesco and Servais, Aude and Hollak, Carla E M and Levtchenko, Elena N and Olde Engberink, Rik H G},
title = {Cystine-Binding Medication Is Poorly Accessible for the Treatment of Cystinuria},
journal = {Kidney and Blood Pressure Research},
year = {2026},
volume = {51},
number = {1},
pages = {729--736},
doi = {10.1159/000553298}
}
EUVIMED